Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a biotechnology company engaged in the discovery, development, manufacturing and commercialization of small molecule drugs for the treatment of serious diseases, on Monday, reported that the new cystic fibrosis drug Kalydeco when combined with its experimental treatment for the disease led to substantially improved breathing ability in a mid-stage study.
Continue reading Vertex Pharmaceuticals Shares Surge on Encouraging Clinical Data (VRTX)